Characteristics of patients with MM who were treated with ide-cel CAR-T therapy
Patient characteristics . | Total cohort (N = 33) . |
---|---|
Age, y | |
Median (range) | 62 (56-67) |
>65, n (%) | 10 (30.3) |
Gender, n (%) | |
Female | 10 (30.3) |
Male | 23 (69.7) |
Race, n (%) | |
White | 24 (72.7) |
Black | 7 (21.2) |
Other | 2 (6.1) |
Diagnosis, n (%) | |
CR | 9 (27.2) |
VGPR | 5 (15.2) |
PR | 5 (15.2) |
ECOG performance score, n (%) | |
0-1 | 24 (72.7) |
≥2 | 4 (12.1) |
Unknown | 5 (15.1) |
Extramedullary disease, n (%) | |
No | 20 (60) |
Yes | 13 (40) |
Previous lines of therapy, n (%) | |
3-4 | 6 (18) |
5-6 | 10 (30) |
>6 | 17 (52) |
Autologous stem cell transplantation history (yes or no), n (%) | |
Yes | 30 (90.91) |
No | 3 (9.09) |
Bridging therapy (yes or no), n (%) | |
Yes | 26 (79) |
No | 7 (21) |
R-ISS staging at CAR-T infusion, n (%) | |
I | 5 (15) |
II | 16 (49) |
III | 12 (36) |
Patient characteristics . | Total cohort (N = 33) . |
---|---|
Age, y | |
Median (range) | 62 (56-67) |
>65, n (%) | 10 (30.3) |
Gender, n (%) | |
Female | 10 (30.3) |
Male | 23 (69.7) |
Race, n (%) | |
White | 24 (72.7) |
Black | 7 (21.2) |
Other | 2 (6.1) |
Diagnosis, n (%) | |
CR | 9 (27.2) |
VGPR | 5 (15.2) |
PR | 5 (15.2) |
ECOG performance score, n (%) | |
0-1 | 24 (72.7) |
≥2 | 4 (12.1) |
Unknown | 5 (15.1) |
Extramedullary disease, n (%) | |
No | 20 (60) |
Yes | 13 (40) |
Previous lines of therapy, n (%) | |
3-4 | 6 (18) |
5-6 | 10 (30) |
>6 | 17 (52) |
Autologous stem cell transplantation history (yes or no), n (%) | |
Yes | 30 (90.91) |
No | 3 (9.09) |
Bridging therapy (yes or no), n (%) | |
Yes | 26 (79) |
No | 7 (21) |
R-ISS staging at CAR-T infusion, n (%) | |
I | 5 (15) |
II | 16 (49) |
III | 12 (36) |
ECOG, Eastern Cooperative Oncology Group; R-ISS, Revised International Staging System.